This Biotech Stock Soars 107% After Key FDA Panel Vote on Skin Cancer Treatment - barrons.com

Replimune Group (REPLI) surged 107% Friday after a Food and Drug Administration advisory committee voted that the company's clinical study on its experimental skin cancer treatment demonstrated "clinically meaningful" results. The panel's endorsement clears a critical regulatory hurdle for the biotech's oncolytic immunotherapy candidate.

FDA advisory committee votes are non-binding but carry substantial weight in final approval decisions. A positive recommendation significantly increases the probability that the agency will grant marketing authorization for the therapy, which targets cutaneous melanoma. The 107% single-day gain reflects investors repricing the asset for a likely commercial launch.

Replimune specializes in oncolytic virus-based treatments designed to selectively target and destroy cancer cells while stimulating an immune response. The company has been developing its lead candidate through late-stage trials, and Friday's panel vote validates the clinical efficacy data presented to regulators.

The FDA typically follows advisory committee recommendations in the majority of cases, making this vote a strong signal for approval timing and commercial viability.